DDInter915 DDInter1077
Indacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and chronic obstructive pulmonary disease. It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as Onbrez and in America as Arcapta Neohaler. Indacaterol is provided as its maleate salt form. Indacaterol is also a chiral molecule but only the pure R-enantiomer is dispensed.
Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist.[Label,A6932] Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmitic acid) with a glutamic acid spacer on the remaining lysine residue at position 26 of the peptide precursor. Liraglutide was granted FDA approval on January 25, 2010.
Indacaterol {u} (Compound) treats {v} (Disease) asthma
asthma {u} (Disease) is treated by {v} (Compound) Hydrocortisone
Hydrocortisone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Liraglutide
Indacaterol {u} (Compound) binds {v} (Gene) ADRB1
ADRB1 {u} (Gene) is bound by {v} (Compound) Formoterol
Formoterol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Liraglutide
Indacaterol {u} (Compound) treats {v} (Disease) asthma
asthma {u} (Disease) is palliated by {v} (Compound) Pseudoephedrine
Pseudoephedrine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Liraglutide
Indacaterol {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Acetaminophen
Acetaminophen {u} may cause a minor interaction that can limit clinical effects when taken with {v} Liraglutide
Indacaterol {u} (Compound) is included by {v} (Pharmacologic Class) Adrenergic beta2-Agonists
Adrenergic beta2-Agonists {u} (Pharmacologic Class) includes {v} (Compound) Salbutamol
Salbutamol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Liraglutide
Indacaterol {u} (Compound) causes {v} (Side Effect) Cardiac disorder
Cardiac disorder {u} (Side Effect) is caused by {v} (Compound) Acetaminophen
Acetaminophen {u} may cause a minor interaction that can limit clinical effects when taken with {v} Liraglutide
Indacaterol {u} (Compound) causes {v} (Side Effect) Atrial fibrillation
Atrial fibrillation {u} (Side Effect) is caused by {v} (Compound) Dopamine
Dopamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Liraglutide
Indacaterol {u} (Compound) causes {v} (Side Effect) Nasopharyngitis
Nasopharyngitis {u} (Side Effect) is caused by {v} (Compound) Gatifloxacin
Gatifloxacin {u} may lead to a major life threatening interaction when taken with {v} Liraglutide
Indacaterol {u} (Compound) binds {v} (Gene) ADRB2
ADRB2 {u} (Gene) is upregulated by {v} (Compound) Vorinostat
Vorinostat {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Liraglutide
Indacaterol {u} (Compound) causes {v} (Side Effect) Nasopharyngitis
Nasopharyngitis {u} (Side Effect) is caused by {v} (Compound) Pasireotide
Pasireotide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Liraglutide
Indacaterol (Compound) treats asthma (Disease) and asthma (Disease) is treated by Hydrocortisone (Compound) and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Indacaterol (Compound) binds ADRB1 (Gene) and ADRB1 (Gene) is bound by Formoterol (Compound) and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Indacaterol (Compound) treats asthma (Disease) and asthma (Disease) is palliated by Pseudoephedrine (Compound) and Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Indacaterol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Acetaminophen (Compound) and Acetaminophen may cause a minor interaction that can limit clinical effects when taken with Liraglutide
Indacaterol (Compound) is included by Adrenergic beta2-Agonists (Pharmacologic Class) and Adrenergic beta2-Agonists (Pharmacologic Class) includes Salbutamol (Compound) and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Indacaterol (Compound) causes Cardiac disorder (Side Effect) and Cardiac disorder (Side Effect) is caused by Acetaminophen (Compound) and Acetaminophen may cause a minor interaction that can limit clinical effects when taken with Liraglutide
Indacaterol (Compound) causes Atrial fibrillation (Side Effect) and Atrial fibrillation (Side Effect) is caused by Dopamine (Compound) and Dopamine may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Indacaterol (Compound) causes Nasopharyngitis (Side Effect) and Nasopharyngitis (Side Effect) is caused by Gatifloxacin (Compound) and Gatifloxacin may lead to a major life threatening interaction when taken with Liraglutide
Indacaterol (Compound) binds ADRB2 (Gene) and ADRB2 (Gene) is upregulated by Vorinostat (Compound) and Vorinostat may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Indacaterol (Compound) causes Nasopharyngitis (Side Effect) and Nasopharyngitis (Side Effect) is caused by Pasireotide (Compound) and Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide